COMMUNIQUÉS West-GlobeNewswire

Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
09/06/2025
First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ [...]
George Medicines announces FDA approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a new single pill combination treatment for hypertension in adults, including initial treatment
09/06/2025
Novel, single pill, triple combination with a standard dose and two lower doses that can deliver the efficacy benefits of combination therapy , with an established safety profile and good tolerability First and only [...]
Keros Announces Return of $375 Million in Excess Capital to Stockholders
09/06/2025
Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical- [...]
Portage Biotech and Compedica Stock-for-Stock Exchange
09/06/2025
DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 [...]
Liver Canada delivers a wake-up call to Canada in new PSA
09/06/2025
TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Liver Canada is confronting the silent epidemic of liver disease with a powerful new public service announcement (PSA) titled Wake-Up Call . The campaign seeks to challenge [...]
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
09/06/2025
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical [...]
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
09/06/2025
PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency ( [...]
AB Science annonce l’approbation par l’EMA de la prolongation de la durée de conservation de Masivet à 4 ans
09/06/2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE L'APPROBATION PAR L'EMA DE LA PROLONGATION DE LA DURÉE DE CONSERVATION DE MASIVET® À 4 ANS Paris, 9 juin 2025, 8h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui [...]
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
09/06/2025
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING Nantes, June 9th, 2025, 8 a.m. - OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnemo: OSE) informs its shareholders and the market of the update on the terms of [...]
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE
09/06/2025
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE Nantes, France, 9 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), informe ses actionnaires et le marché de la mise à jour des modalités [...]
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
09/06/2025
Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad [...]
Communiqué de presse : Sanofi accélère la livraison mondiale de Beyfortus pour préparer les professionnels de santé plusieurs mois avant la saison 2025-2026 de VRS
09/06/2025
Sanofi accélère la livraison mondiale de Beyfortus pour préparer les professionnels de santé plusieurs mois avant la saison 2025-2026 de VRS Paris, le 9 juin 2025. Sanofi livrera Beyfortus (nirsevimab) dès le début du [...]
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
08/06/2025
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of [...]
Ro Weight Loss Announces Official Website Update Featuring Natural Daily Program for Medically-Guided Weight Management
07/06/2025
Digital health platform offers FDA-approved treatments when appropriate and personalized care plans through licensed providers. New York, June 07, 2025 (GLOBE NEWSWIRE) -- Ro Weight Loss, a digital health service from [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/06/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/06/2025
CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
06/06/2025
VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“ Rakovina ” or the “ Company ”), a biopharmaceutical company advancing innovative cancer therapies [...]
RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
06/06/2025
MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/06/2025
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]

Pages